公开(公告)号：US20100233701A1

公开(公告)日：2010-09-16

申请号：US12655368

申请日：2009-12-28

申请人： Henry H. Heng ,  Christine Ye a/k/a Jing Ye

发明人： Henry H. Heng ,  Christine Ye a/k/a Jing Ye

IPC分类号： C12Q1/68

CPC分类号： C12Q1/6886 ,  C12Q2600/106

摘要： A diagnostic method of determining tumorigenicity of a tissue specimen includes the steps of determining the magnitude of genome diversity in the tissue specimen, and diagnosing a likelihood of cancer in response thereto. The magnitude of genome diversity includes the determination of karyotypic heterogeneity in tissue specimen, illustratively by detecting non-clonal chromosome aberrations (NCCAs). The detection of NCCAs includes the identification of various types and frequency of NCCAs, and diagnosis is responsive to the step of detecting the frequency of NCCAs. Detection of NCCAs includes the further step of screening lymphocytes. Also, the step of determining the presence of elevated genome diversity includes the step of applying Spectral Karyotyping to detect structural and numerical aberrations throughout the genome. The diagnostic method is useful to determine drug resistance in a patient and potential harmfulness, to evaluate the side effects of drugs, and to measure genome system stress.

摘要翻译： 确定组织标本的致瘤性的诊断方法包括以下步骤：确定组织标本中基因组多样性的大小，并响应于此诊断癌症的可能性。 基因组多样性的大小包括组织标本中核型异质性的测定，例如通过检测非克隆染色体畸变（NCCA）。 NCCA的检测包括NCCAs的各种类型和频率的识别，诊断响应于检测NCCA频率的步骤。 NCCA的检测包括进一步筛选淋巴细胞的步骤。 此外，确定升高的基因组多样性的存在的步骤包括应用光谱核型分析来检测整个基因组中的结构和数值畸变的步骤。 诊断方法有助于确定患者的耐药性和潜在的危害，评估药物的副作用，并测量基因组系统应激。

公开(公告)号：US20100086934A1

公开(公告)日：2010-04-08

申请号：US12583194

申请日：2009-08-14

申请人： Henry H. Heng ,  Christine Ye

发明人： Henry H. Heng ,  Christine Ye

IPC分类号： C12Q1/68

CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/118

摘要： A diagnostic method of determining tumorigenicity of a tissue specimen includes the steps of determining a magnitude of genome diversity in the tissue specimen, and diagnosing a likelihood of cancer in response to said step of determining the magnitude of genome diversity. The magnitude of genome diversity includes the determination of karyotypic heterogeneity in the tissue specimen, illustratively by detecting non-clonal chromosome aberrations (NCCAs). The detection of NCCAs includes the detection the frequency of NCCAs, and the diagnosis is responsive to the step of detecting the frequency of NCCAs. Detection of NCCAs advantageously includes the further step of screening lymphocytes. Also, the step of determining the presence of elevated genome diversity includes the step of applying Spectral Karyotyping to detect translocations throughout the genome. The diagnostic method is useful to determine drug resistance of a patient.

摘要翻译： 确定组织标本的致瘤性的诊断方法包括以下步骤：响应于确定基因组多样性的大小的步骤，确定组织标本中基因组多样性的大小，以及诊断癌症的可能性。 基因组多样性的大小包括确定组织标本中的核型异质性，说明性地通过检测非克隆染色体畸变（NCCAs）。 NCCA的检测包括检测NCCA的频率，诊断响应于检测NCCA频率的步骤。 NCCA的检测有利地包括筛选淋巴细胞的进一步步骤。 此外，确定升高的基因组多样性的存在的步骤包括应用光谱核型分析以检测整个基因组的易位的步骤。 该诊断方法可用于确定患者的耐药性。